<DOC>
	<DOC>NCT00891332</DOC>
	<brief_summary>This is a multicenter study designed to evaluate the response rate of S-1 plus Leucovorin (1 week on and 1 week off) as first -line treatment for patients with metastatic colorectal cancer.</brief_summary>
	<brief_title>Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Histologically proved adenocarcinoma Unresectable and recurrent colorectal cancer Age20 â‰¤ at enrollment Performance status 0 or 1 (ECOG) No prior treatment (ex. radiation therapy, chemotherapy, hormonal therapy) to advanced disease. Patients who received adjuvant chemotherapy more than 180 days before enrollment can be allowed but those who received S1 containing treatment shall be excluded Adequate hematologic, hepatic and renal functions At least one measurable lesion by RECIST criteria Serious drug hypersensitivity Pregnant or nursing Bleeding from gastrointestinal tract Diarrhea Simultaneously active double cancer Serious illness or medical condition Brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>